Last reviewed · How we verify
Dimephosphon®
Dimephosphon is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity and promoting osteoclast apoptosis.
Dimephosphon is a bisphosphonate that inhibits bone resorption by suppressing osteoclast activity and promoting osteoclast apoptosis. Used for Osteoporosis, Paget's disease of bone, Bone metastases.
At a glance
| Generic name | Dimephosphon® |
|---|---|
| Sponsor | Tatchempharmpreparaty, JSC |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase (indirect); osteoclast function |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
As a bisphosphonate, dimephosphon binds to hydroxyapatite in bone and is internalized by osteoclasts during bone resorption. Once inside osteoclasts, it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting the prenylation of small GTPases essential for osteoclast function and survival. This leads to osteoclast apoptosis and reduced bone turnover, making it useful in conditions characterized by excessive bone loss.
Approved indications
- Osteoporosis
- Paget's disease of bone
- Bone metastases
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Musculoskeletal pain
- Osteonecrosis of the jaw
- Atypical fractures
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimephosphon® CI brief — competitive landscape report
- Dimephosphon® updates RSS · CI watch RSS
- Tatchempharmpreparaty, JSC portfolio CI